Wiley Blackwell

SHERPA: Unknown

People

  1. Motzer
    Motzer
  2. Kemeny
    Kemeny
  3. Horwitz
    Horwitz
  4. Marghoob
    Marghoob
  5. Kelsen
    Kelsen
  6. Scher
    Scher
  7. Hudis
    Hudis
  8. O'Reilly
    O'Reilly
  9. Tuttle
    Tuttle
  10. Bajorin
    Bajorin

Groups

  1. Department of Medicine (1537)
  2. Solid Tumor Oncology Division (892)
  3. Survivorship Research (499)
  4. Hematologic Malignancies, Division of (432)
  5. Division of Subspecialty Medicine (380)
  6. Center for Hematologic Malignancies (343)
  7. Population Sciences Research Program (289)
  8. Genitourinary Oncology Service (269)
  9. GSK Faculty (263)
  10. Surgery (257)
Search Within
  1. "Department of Medicine"
Formats
  1. Journal Article (982)
  2. Meeting Abstract (382)
  3. Review (52)
  4. Book Section (37)
  5. Research Letter (28)
  6. Editorial (26)
  7. Conference Paper (13)
  8. Guidelines (8)
  9. Correspondence (6)
  10. Miscellaneous (2)
  11. Book Whole (1)
Groups
  1. Department of Medicine (1537)
  2. Solid Tumor Oncology Division (892)
  3. Survivorship Research (499)
  4. Hematologic Malignancies, Division of (432)
  5. Division of Subspecialty Medicine (380)
  6. Center for Hematologic Malignancies (343)

More Groups

People
  1. Robert Motzer (87)
  2. Nancy Kemeny (59)
  3. Steven Horwitz (55)
  4. Ashfaq Marghoob (53)
  5. David Kelsen (49)
  6. Howard Scher (46)

More People

Years
  1. 2025 (48)
  2. 2024 (60)
  3. 2023 (133)
  4. 2022 (54)
  5. 2021 (106)
  6. 2020 (81)

More Years

Publications
  1. Cancer (541)
  2. Hematological Oncology (167)
  3. BJU International (75)
  4. Journal of Surgical Oncology (61)
  5. Asia-Pacific Journal of Clinical Oncology (58)
  6. Cancer Medicine (58)

More Publications

Results (1537)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Hypertension (HTN) in patients (pts) treated with ibrutinib (IBR) for chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Sarraf Yazdy, M.; Roeker, L.; Gashonia, L.; Goodfriend, J.; Narkhede, M.; Rhodes, J.; Kennard, K.; Morse, H.; Dorsey, C.; Battiato, K.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Ibrutinib for the treatment of Bing‐Neel syndrome: A retrospective, multicenter study
    Meeting Abstract

    Castillo, J.; Itchaki, G.; Paludo, J.; Varettoni, M.; Buske, C.; Eyre, T.; Chavez, J.; Shain, K.; Issa, S.; Palomba, L.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Ibrutinib monotherapy produces long‐term disease control in previously treated Waldenstrom's macroglobulinemia. Final report of the pivotal trial (NCT01614821)
    Meeting Abstract

    Treon, S. P.; Meid, K.; Gustine, J.; Yang, G.; Xu, L.; Patterson, C. J.; Ghobrial, I.; Laubach, J. P.; Hunter, Z. R.; Dubeau, T.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Phase I clinical trial of CD19‐targeted 19‐28z/4‐1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter transformation
    Meeting Abstract

    Batlevi, C. L.; Palomba, M. L.; Park, J.; Mead, E.; Santomasso, B.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R.; Yang, J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • EZH2 gain‐of‐function mutations are not associated with more favorable prognosis in relapsed/refractory follicular lymphoma (FL): A preliminary analysis on 590 patients
    Meeting Abstract

    Okosun, J.; Bödör, C.; Batlevi, C.; Nagy, N.; Michot, J.; Schneider, T.; Alizadeh, H.; Simon, Z.; Vose, J.; Younes, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Concordance between immunohistochemistry and gene expression profiling subtyping for diffuse large B‐cell lymphoma in the phase 3 PHOENIX trial
    Meeting Abstract

    Balasubramanian, S.; Wang, S.; Major, C.; Hodkinson, B.; Schaffer, M.; Sehn, L. H.; Johnson, P.; Zinzani, P. L.; Carey, J.; Liu, G.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B‐cell lymphoma: Efficacy and safety from the phase 2 CheckMate 436 study
    Meeting Abstract

    Zinzani, P. L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P. M.; Kuruvilla, J.; Cunningham, D.; Kline, J.; Johnson, N. A.; Mehta‐Shah, N. A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Impact of pet imaging and histologic transformation on the prognosis of early disease progression in follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Hamlin, P.; Horwitz, S. M.; Kumar, A.; Matasar, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • A phase 2 study to assess the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy
    Meeting Abstract

    Mato, A. R.; Schuster, S. J.; Lamanna, N.; Pagel, J. M.; Flinn, I. W.; Barrientos, J.; Reeves, J. A.; Cheson, B. D.; Barr, P. M.; Kambhampati, S.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save